Navigation Links
Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Date:5/15/2012

difficulty swallowing.  By providing a once-daily regimen for patients with moderate to severe Alzheimer's disease, Arimenda will meet the market need for a therapy that has the potential to ease caregiver burden, extend the duration of homecare, and delay the admission of patients to costly skilled nursing facilities.  Arimenda will be investigated in a Phase 3 safety study of up to 300 subjects to be conducted at approximately 50 centers in the United States and rest of the world. 

About Alzheimer's Disease

Alzheimer's disease is a chronic, progressive neurodegenerative condition that afflicts over 50 million patients worldwide including more than 5 million sufferers in the United States. The direct healthcare costs exceed $200 billion driven by moderate to severe patients who require care in nursing facilities and assisted living facility.  Caregiver burden is a second significant economic cost of the disease with 15 million caregivers providing 17 billion hours of unpaid care to dementia patients per year, valued at over $200 billion. The treated population is forecast to increase from the current 2.2 million to nearly 3.5 million by 2020.  

There is no cure on the horizon for Alzheimer's disease or for other diseases that cause dementia. Progression of dementia leads to dependence on caregivers and family, who struggle with managing activities of daily living, behavioral challenges, and complicated dosing regimens of the multiple medications that most dementia patients require. Recent outcome studies have shown that memantine and donepezil combination therapy, as compared to monotherapy, significantly increases the time nursing home admissions and significantly reduces health care costs. Despite these benefits, less than 30% of patients are currently treated with combination therapy. Adamas' Arimenda is specifically designed to address these issues, increasing the access to combination
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
5. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
10. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 According to ... "Orthopedic Trauma Fixation Devices Market - Global Forecast, Market ... the global orthopedic trauma fixation devices market is estimated ... to grow at a CAGR of 7.2% from 2014 ... 9.3 billion in 2020. Browse the Orthopedic ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today announced ... new corporate logo. This is part of a comprehensive rebranding ... Founded in Boston, MA , in 1959, ... companies since 1992.  Other companies in the group include Inova ... Systelab ( Barcelona, Spain ).  Like IL, these ...
(Date:7/29/2014)... DUBLIN , July 29, 2014 ... the "Global Respiratory Devices Market 2014-2018" report ... A respiratory device is a medical ... who is having difficulty in breathing and cannot achieve ... disorders such as cystic fibrosis, asthma, COPD, and ARDS ...
Breaking Medicine Technology:Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2
... MOSCOW, Jan. 3, 2012 Goodwin Biotechnology, Inc. (GBI) ... announced an agreement for cell line engineering and manufacturing ... line. The monoclonal antibody will be engineered by GBI,s ... lines, select the highest producer and manufacture the monoclonal ...
... 3, 2012 /PRNewswire-Asia/ -- The Ministry of Health and Welfare ... Kyung-Hwa) announced that a 19-year-old woman, Tan Hui-Linn, has been ... Korea project and will receive surgery at the JK Plastic ... life that was once full of hopes shattered on Oct. ...
Cached Medicine Technology:Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 2Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 3Acid Attack Victim from Malaysia Restores Her Lost Face with Support of Medical Korea 2
(Date:7/30/2014)... According to the Yeast Infection No More book review ... will help candida sufferers get rid of their yeast ... to readers the truth about yeast infection and the real ... will discover natural and safe remedies to relieve symptoms of ... irritation of the vagina or vulva. , Vkool reveals ...
(Date:7/30/2014)... Seattle, WA (PRWEB) July 30, 2014 According ... by Vkool.com, this is a comprehensive bodybuilding guide for men ... press by up to 50 pounds in within a ... routine that will help keep their shoulders healthy and avoid ... that the Critical Bench Program 2.0 uncovers to learners the ...
(Date:7/30/2014)... Kennewick, WA (PRWEB) July 30, 2014 ... today availability of over 80 different electronic therapy ... notes on tablets and other computing devices all ... 80+ therapy notes or electronic medial records (EMR) ... initial evaluations, and other essential categories. SOAP ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 pMD, ... physician communication, launched an Observation Result (ORU) interface ... hospital. pMD’s cardiology customers are using the ORU ... for their test interpretations for electrocardiograms, echocardiograms, and ... in the hospital, the cardiology system produces electronic ...
(Date:7/30/2014)... TN (PRWEB) July 30, 2014 Regents ... medical imaging services, has brought health care industry veteran ... on board to help lead the company’s ambitious plans ... , “Regents Health has been moving along at a ... to kick it up a notch,” says Bob Maier, ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Sferrella and Demonbreun Join Regents Health Resources 2
... Nov. 27 S*BIO Pte Ltd today announced ... development,candidate, SB1317. This is a novel orally-available small ... SB1317 is designed to selectively inhibit major ... progression in acute,leukemias. Flt3 mutations are the most ...
... NEWTOWN SQUARE, Pa., Nov. 27 In its ... homeopathy, Boiron,Laboratories disputes an editorial comment published in ... that its author has misinterpreted results of,clinical trials ... journal features an editorial by Ben Goldacre on,the ...
... reflect reports of bizarre behaviors and sudden deaths ... U.S. Food and Drug Administration advisory panel recommended Tuesday ... a stronger warning label to reflect reports of bizarre ... , The FDA,s Pediatric Advisory Committee, in a 9-5 ...
... Nov. 27 Zimmer Holdings, Inc.,(NYSE: ZMH ; ... resign,as Chairman of the Board and a member of ... years of service with the Company. John L.,McGoldrick, a ... Mr. Elliott served as Chairman, President and Chief Executive ...
... Pronounced "mursa,",methicillin-resistant staphylococcus aureus (MRSA) is one of ... about it. It has,killed the elderly, babies, toddlers, teenagers ... closing public schools., One of the most common ... infection can start innocently, perhaps with a nick or ...
... 90%+ Success Rate..., CLEARWATER, Fla., Nov. 27 ... announced,today that it has certified over 600 surgeons in ... were trained in the basic technique at the,North American ... "We believe that this milestone is a reasonable ...
Cached Medicine News:Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 3Health News:FDA Panel Backs Tougher Warning for Tamiflu 2Health News:FDA Panel Backs Tougher Warning for Tamiflu 3Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 2Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 3Health News:New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Family's Feet 2Health News:Over 600 Surgeons Certified to use TruFUSE(R) to Treat Back Pain Sufferers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: